Al-Mulla, N.A. and Chandra, P. and Khattab, M. and Madanat, F. and Vossough, P. and Torfa, E. and Al-Lamki, Z. and Zain, G. and Muwakkit, S. and Mahmoud, S. and Al-Jassmi, A. and Tuncer, M. and Al-Mukharraq, H. and Barsaoui, S. and Arceci, R.J. and Howard, S.C. and Kulozik, A.E. and Ravindranath, Y. and Reaman, G.H. and Farranoush, M. and Alnasser, A.A. (2014) Childhood acute lymphoblastic leukemia in the Middle East and neighboring countries: A prospective multi-institutional international collaborative study (CALLME1) by the Middle East Childhood Cancer Alliance (MECCA). Pediatric Blood and Cancer, 61 (8). pp. 1403-1410.
|
Text
Childhood acute lymphoblastic leukemia in the Middle East and neighboring countries A prospective multi-institutional international collaborative study (CALLME1) by the Middle East Childhood Cancer Alliance.pdf Download (1MB) | Preview |
Abstract
Background: Little is known about childhood ALL in the Middle East. This study was undertaken by MECCA as initial efforts in collaborative data collection to provide clinical and demographic information on children with ALL in the Middle East. Procedure: Clinical and laboratory data for patients with ALL between January 2008 and April 2012 were prospectively collected from institutions in 14 Middle East countries and entered into a custom-built-database during induction phase. All laboratory studies including cytogenetics were done at local institutions. Results: The 1,171 voluntarily enrolled patients had a mean age of 6.1±3.9 years and 59.2 were boys. T-ALL represented 14.8 and 84.2 had B-precursor ALL. At diagnosis, 5.6 had CNS disease. The distribution of common genetic abnormalities reflected a similar percentage of hyperdiploidy (25.6), but a lower percentage of ETV6-RUNX1 translocation (14.7) compared to large series reported from Western populations. By clinical criteria, 47.1 were low/standard risk, 16.9 were intermediate risk, and 36 were high risk. Most patients received all their care at the same unit (96.9). Patients had excellent induction response to chemotherapy with an overall complete remission rate of 96. Induction toxicities were acceptable. Conclusions: This first collaborative study has established a process for prospective data collection and future multinational collaborative research in the Middle East. Despite the limitations of an incomplete population-based study, it provides the first comprehensive baseline data on clinical characteristics, laboratory evaluation, induction outcome, and toxicity. Further work is planned to uncover possible biologic differences of ALL in the region and to improve diagnosis and management. Pediatr Blood Cancer 2014; 61:1403-1410. © 2014 Wiley Periodicals, Inc.
| Item Type: | Article |
|---|---|
| Additional Information: | cited By 7 |
| Uncontrolled Keywords: | antineoplastic agent; BCR ABL protein; hemoglobin; phosphorus; potassium; transcription factor 7 like 1; transcription factor ETV6; transcription factor PBX1; transcription factor RUNX1; uric acid, acute lymphoblastic leukemia; adolescent; adult; anaphylaxis; article; avascular necrosis; bleeding; bone marrow; bone necrosis; bone pain; bronchospasm; cancer chemotherapy; cancer mortality; child; childhood leukemia; comorbidity; constipation; cytogenetics; diarrhea; diploidy; Down syndrome; female; fever; flow cytometry; fluorescence in situ hybridization; gastritis; gene rearrangement; gene translocation; genetic risk; Gram negative sepsis; gram positive sepsis; heart arrhythmia; heart failure; hematologic disease; hepatomegaly; human; human cell; hyperdiploidy; immune deficiency; immunophenotyping; induction chemotherapy; infant; karyotyping; leukemia remission; leukocyte count; lymphadenopathy; major clinical study; male; Middle East; motor neuropathy; mycosis; myelodysplastic syndrome; oral mucositis; osteoporosis; pallor; pancreatitis; paralysis; petechia; polymerase chain reaction; pre B lymphocyte; priority journal; scrotal swelling; seizure; sensory neuropathy; sepsis; shock; skin bruising; splenomegaly; steroid therapy; thrombocyte count; treatment response; tumor lysis syndrome; typhlitis; urticaria, induction; leukemia; MECCA; pediatric, Adolescent; Child; Child, Preschool; Core Binding Factor Alpha 2 Subunit; Disease-Free Survival; Female; Humans; Infant; Male; Middle East; Oncogene Proteins, Fusion; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Survival Rate; Translocation, Genetic |
| Subjects: | WH Hemic and Lymphatic Systems |
| Depositing User: | Ms Roya Vesal Azad |
| Date Deposited: | 26 Feb 2019 10:30 |
| Last Modified: | 26 Feb 2019 10:30 |
| URI: | http://eprints.iums.ac.ir/id/eprint/11832 |
Actions (login required)
 |
View Item |
